BRD4 inhibitors block telomere elongation
Open accessPublished version of a preprint
The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.
Abstract
Cancer cells maintain telomere length equilibrium to avoid senescence and apoptosis induced by short telomeres, which trigger the DNA damage response. Limiting the potential for telomere maintenance in cancer cells has been long been proposed as a therapeutic target. Using an unbiased shRNA screen targeting known kinases, we identified bromodomain-containing protein 4 (BRD4) as a telomere length regulator. Four independent BRD4 inhibitors blocked telomere elongation, in a dose-dependent manner, in mouse cells overexpressing telomerase. Long-term treatment with BRD4 inhibitors caused telomere shortening in both mouse and human cells, suggesting BRD4 plays a role in telomere maintenance in vivo. Telomerase enzymatic activity was not directly affected by BRD4 inhibition. BRD4 is in clinical trials for a number of cancers, but its effects on telomere maintenance have not been previously investigated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Moreover, BRD4 was shown to positively regulate telomere elongation in murine and human cultures105.”
From Cellular senescence in ageing: from mechanisms to therapeutic opportunities (2021) · cites this paper as [105]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular Cloning: A Laboratory Manual
Sambrook, J., Fritsch, E., & Maniatis, T. (1989) · UCLA - Biblioteca de Ciencias de la Salud · Cited by 133,589
Fast gapped-read alignment with Bowtie 2
Langmead, B., & Salzberg, S. L. (2012) · Nature Methods · doi:10.1038/nmeth.1923 · Cited by 56,400
Telomeres shorten during ageing of human fibroblasts
Harley, C. B., Futcher, A. B., & Greider, C. W. (1990) · Nature · doi:10.1038/345458a0 · Cited by 5,750
Self-citationSelective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262 · cited 11×
“JQ1 (Selleckchem S7110), OTX015 (Selleckchem S7360), I-BET151 (Selleckchem S2780), and MS436 (Selleckchem S7305) were used to inhibit BRD4.”
BackgroundInfluentialIdentification of a specific telomere terminal transferase activity in tetrahymena extracts
Greider, C. W., & Blackburn, E. H. (1985) · Cell · doi:10.1016/0092-8674(85)90170-9 · Cited by 3,400 · cited 1×
“Telomerase elongates telomeres and maintains a telomere length equilibrium that prevents telomeres from becoming critically short (5).”
BackgroundSelf-citationA DNA damage checkpoint response in telomere-initiated senescence
Fagagna, F. D. D., Reaper, P. M., Clay-Farrace, L., Fiegler, H., Carr, P., von Zglinicki, T., Saretzki, G., Carter, N. P., & Jackson, S. P. (2003) · Nature · doi:10.1038/nature02118 · Cited by 2,917
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Delmore, J. E., Issa, G. C., Lemieux, M. E., Rahl, P. B., Shi, J., Jacobs, H. M., Kastritis, E., Gilpatrick, T., Paranal, R. M., Qi, J., et al. (2011) · Cell · doi:10.1016/j.cell.2011.08.017 · Cited by 2,813
Li, W., Xu, H., Xiao, T., Cong, L., Love, M. I., Zhang, F., Irizarry, R. A., Liu, J. S., Brown, M., & Liu, X. S. (2014) · Genome Biology · doi:10.1186/s13059-014-0554-4 · Cited by 2,684 · cited 7×
“Bioinformatic analysis Illumina reads were aligned to reference sequences using Bowtie2 as described (42,43), and enriched genes were determined by evaluating 3 biological replicates with MAGeCK analysis (44).”
MethodInfluentialTargeting cancer with small molecule kinase inhibitors
Zhang, J., Yang, P. L., & Gray, N. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2559 · Cited by 2,576
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
Zuber, J., Shi, J., Wang, E., Rappaport, A. R., Herrmann, H., Sison, E. A., Magoon, D., Qi, J., Blatt, K., Wunderlich, M., et al. (2011) · Nature · doi:10.1038/nature10334 · Cited by 1,870 · cited 1×
“BRD4 translocations are linked to cancer, and BRD4 inhibition reduces cell proliferation in acute myeloid leukemia (63,64), potentially by blocking BRD4 mediated transcription of c-MYC.”
Background
Cited by
Cellular senescence in ageing: from mechanisms to therapeutic opportunities
Di Micco, R., Krizhanovsky, V., Baker, D., & d’Adda di Fagagna, F. (2021) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-00314-w · Cited by 2,277
BRD4 and Cancer: going beyond transcriptional regulation
Donati, B., Lorenzini, E., & Ciarrocchi, A. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0915-9 · Cited by 708
Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets
Yang, J., Xu, J., Wang, W., Zhang, B., Yu, X., & Shi, S. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01480-x · Cited by 388
Targeting histone acetylation in pulmonary hypertension and right ventricular hypertrophy
Chelladurai, P., Boucherat, O., Stenmark, K. R., Kracht, M., Seeger, W., Bauer, U., Bonnet, S., & Pullamsetti, S. S. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14932 · Cited by 123
BET proteins: Biological functions and therapeutic interventions
Guo, J., Zheng, Q., & Peng, Y. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108354 · Cited by 98
Inhibition of BET Proteins and Histone Deacetylase (HDACs): Crossing Roads in Cancer Therapy
Manzotti, G., Ciarrocchi, A., & Sancisi, V. (2019) · Cancers · doi:10.3390/cancers11030304 · Cited by 91
BRD4 in physiology and pathology: ‘‘BET’’ on its partners
Liang, Y., Tian, J., & Wu, T. (2021) · BioEssays · doi:10.1002/bies.202100180 · Cited by 76
TIN2 Functions with TPP1/POT1 To Stimulate Telomerase Processivity
Pike, A. M., Strong, M. A., Ouyang, J. P. T., Connelly, C. J., & Greider, C. W. (2019) · Molecular and Cellular Biology · doi:10.1128/mcb.00593-18 · Cited by 60
Self-citationBRD4: An emerging prospective therapeutic target in glioma
Yang, H., Wei, L., Xun, Y., Yang, A., & You, H. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.03.005 · Cited by 59
Reyes-Garau, D., Ribeiro, M. L., & Roué, G. (2019) · Cancers · doi:10.3390/cancers11101483 · Cited by 50
CircMEG3 inhibits telomerase activity by reducing Cbf5 in human liver cancer stem cells
Jiang, X., Xing, L., Chen, Y., Qin, R., Song, S., Lu, Y., Xie, S., Wang, L., Pu, H., Gui, X., et al. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.11.009 · Cited by 47
Sun, J., Gui, Y., Zhou, S., & Zheng, X. (2023) · Journal of Advanced Research · doi:10.1016/j.jare.2023.11.006 · Cited by 42
Heterogeneous Nuclear Ribonucleoproteins Involved in the Functioning of Telomeres in Malignant Cells
Ss, S., Ковалев, Л. И., Pashintseva, N. V., Kovaleva, M. A., & Lisitskaya, K. V. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030745 · Cited by 42
Fik, M. A., Mkrtchyan, A. F., Saghyan, A. S., Palumbo, R., Belter, A., Hayriyan, L. A., Simonyan, H. M., Roviello, V., & Roviello, G. N. (2019) · Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy · doi:10.1016/j.saa.2019.117884 · Cited by 40
Xie, F., Xiao, X., Tao, D., Huang, C., Wang, L., Liu, F., Zhang, H., Niu, H., & Jiang, G. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.09.016 · Cited by 40
Telomerase and Telomeres Biology in Thyroid Cancer
Donati, B., & Ciarrocchi, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20122887 · Cited by 30
Yik, M. Y., Azlan, A., Rajasegaran, Y., Rosli, A. A., Yusoff, N. M., & Moses, E. J. (2021) · Genes · doi:10.3390/genes12081188 · Cited by 30
Long noncoding RNA MEG3 blocks telomerase activity in human liver cancer stem cells epigenetically
Jiang, X., Wang, L., Xie, S., Chen, Y., Song, S., Lu, Y., & Lu, D. (2020) · Stem Cell Research & Therapy · doi:10.1186/s13287-020-02036-4 · Cited by 30
Ho, L., Hossen, M. N., Nguyen, T. B., Vo, A., & Ahsan, F. (2022) · Biomedicines · doi:10.3390/biomedicines10010170 · Cited by 29
Yu, X., Long, Q., Shen, S., Liu, Z., Chandran, J., Zhang, J., Ding, H., Zhang, H., Cai, D., Kim, E. S., et al. (2023) · Antiviral Research · doi:10.1016/j.antiviral.2023.105552 · Cited by 29
Caveolin-2 is regulated by BRD4 and contributes to cell growth in pancreatic cancer
Jiao, F., Han, T., Yuan, C., Liang, Y., Cui, J., Zhuo, M., & Wang, L. (2020) · Cancer Cell International · doi:10.1186/s12935-020-1135-0 · Cited by 28
Telomere Shortening in the Alzheimer’s Disease Neuroimaging Initiative Cohort
Nudelman, K. N. H., Lin, J., Lane, K. A., Nho, K. T., Kim, S., Faber, K. M., Risacher, S. L., Foroud, T., Gao, S., Davis, J. W., et al. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190010 · Cited by 24
Fik, M. A., Mkrtchyan, A. F., Saghyan, A. S., Palumbo, R., Belter, A., Hayriyan, L. A., Simonyan, H. M., Roviello, V., & Roviello, G. N. (2020) · Amino Acids · doi:10.1007/s00726-020-02849-w · Cited by 23
Wang, J., Dai, M., Xing, X., Wang, X., Qin, X., Huang, T., Fang, Z., Fan, Y., & Xu, D. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13324 · Cited by 19
Anticancer Effects of I-BET151, an Inhibitor of Bromodomain and Extra-Terminal Domain Proteins
Lai, J., Liu, Z., Zhao, Y., Ma, C., & Huang, H. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.716830 · Cited by 16
Liu, T., Zhang, Z., Wang, C., Huang, H., & Li, Y. (2022) · Biochemistry and Cell Biology · doi:10.1139/bcb-2021-0552 · Cited by 16
Fragment‐Based Drug Discovery in the Bromodomain and Extra‐Terminal Domain Family
Radwan, M., & Serya, R. A. T. (2017) · Archiv der Pharmazie · doi:10.1002/ardp.201700147 · Cited by 13
Interfering with bromodomain epigenome readers as therapeutic option in mucoepidermoid carcinoma
Markman, R. L., Webber, L. P., Filho, C., dos Reis, L. A., Vargas, P. A., Lopes, M. A., Zanella, V. G., Martins, M. D., SQUARIZE, C. H., & CASTILHO, R. M. (2018) · Cellular Oncology · doi:10.1007/s13402-018-0416-2 · Cited by 13
Keener, R., Chhetri, S. B., Connelly, C. J., Taub, M. A., Conomos, M. P., Weinstock, J. S., Ni, B., Strober, B. J., Aslibekyan, S. W., Auer, P. L., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48394-y · Cited by 10
Self-citationLethal activity of BRD4 PROTAC degrader QCA570 against bladder cancer cells
Wang, Q., Li, B., Zhang, W., Li, Z., Jiang, B., Hou, S., Ma, S., & Qin, C. (2023) · Frontiers in Chemistry · doi:10.3389/fchem.2023.1121724 · Cited by 10
Li, Z., Wang, H., Liu, B., & Wang, W. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117418 · Cited by 9
Damaneh, M. S., Hu, J., Huan, X., Song, S., Tian, C., Chen, D.-Q., Meng, T., Chen, Y.-L., Shen, J., Xiong, B., et al. (2019) · Investigational New Drugs · doi:10.1007/s10637-019-00818-z · Cited by 9
Zhang, H., Yu, J., Zhang, F., Liu, Q., Pan, J., Wen, P., Lü, D., Liu, R., Wang, T., & Wang, S. (2025) · Scientific Reports · doi:10.1038/s41598-025-89614-9 · Cited by 9
Self-citationSmall Molecular Immune Modulators as Anticancer Agents
Han, Y., Zhu, L., Wu, W., Zhang, H., Hu, W., Dai, L., & Yang, Y. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-3266-5_22 · Cited by 8
Tang, J., Chen, H., Fan, H., Chen, T., Pu, C., & Guo, Y. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117929 · Cited by 5
Wang, X., Meng, R.-J., Cao, W.-J., Cheng, L., Zhang, J., & Chen, S. (2025) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2025.118473 · Cited by 4
Yu, S., Hu, S., Wang, W., Pan, C., Zhang, H., Zhou, C., Liu, Y., & Rui, L. C. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118644 · Cited by 4
Epigenetic Alterations in Hepatocellular Carcinoma: Mechanisms and Biomarkers for Precision Therapy
Cai, B., Lv, D., Qiu, Q., 熊文举, Tang, H., Bai, Y., Zhou, S., Hu, Y., Safadi, R., Wang, C., et al. (2026) · Cancers · doi:10.3390/cancers18142224 · Cited by 3
BRD4: From molecular understanding to therapeutics development
Wu, S.-Y., & Chiang, C. (2026) · Molecular Cell · doi:10.1016/j.molcel.2026.07.004 · Cited by 3
Wang, J., Ning, J., Zhou, Z., & Li, H. (2025) · Tissue and Cell · doi:10.1016/j.tice.2025.102919 · Cited by 1
MAGNETIC DEVICES IN GLASS APPARATUS. PART II
Gamisch, G., & Ruettiger, W. (1958) · OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information)
Chiang, C. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.739140172.793581483
Role of Metabolism Controlled Histone Posttranslational Modifications in Cancer Biology
Gao, M. (2021) · theses.fr (ABES) · doi:10.70675/407e4899z1e38z49edza20dzfd6750c3b66a
Zhang, T. (2025) · Theoretical and Natural Science · doi:10.54254/2753-8818/2025.au27907
González‐Losada, C. (2025) · eScholarship@McGill (McGill) · doi:10.82308/9153
Lin, W.-H., Kosari, F., Smadbeck, J. B., Barrett, M. T., Feathers, R., Hall, J., Sadeghian, D., Sotiriou, S., Johnson, S. H., Harris, F. R., et al. (2026) · npj Precision Oncology · doi:10.1038/s41698-026-01740-3
Wang, X. L., Ji, J., Ma, Y., Liu, L., Bao, K., Yang, H., Li, Z., Li, T., Shi, L., & Yang, N. (2026) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2026.152638
Cheng, Z., Zou, Z., Xin, M., Wu, S., Lu, G., Du, Z., Chen, X., Chen, G., Cai, Y., & Zou, Y. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.119109
Metadata
- Authors
- Wang, S., Pike, A. M., Lee, S. S., Strong, M. A., Connelly, C. J., & Greider, C. W.
- Affiliations
- Johns Hopkins University (US)
- Corresponding author
- Greider, Carol W.
- ORCID
- Venue
- Nucleic Acids Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-06-30
- Volume
- 45
- Issue
- 14
- Pages
- 8403-8410
- ISSN
- 0305-1048 (ISSN-L)
- 1362-4962
- PMC
- PMC5737673
- OpenAlex
- W2949192443
- Cited by
- 45
- References
- 74
- Citations by year
- 2026: 6 · 2025: 4 · 2024: 1 · 2023: 6 · 2022: 3 · 2021: 4 · 2020: 8 · 2019: 9 · 2018: 2 · 2017: 1
- FWCI
- 4.05
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Nucleic Acids Research (publishedVersion, cc-by-nc)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Johns Hopkins University
- National Institutes of Health
- University of California, Riverside
- National Cancer Institute (R01CA160300)
- National Institute of General Medical Sciences (T32GM008752)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA and Nucleic Acid Chemistry
- Keywords
- BRD4, bromodomain proteins, telomere maintenance, telomere elongation, telomerase, telomere shortening, cancer therapy, shRNA screen, kinases, DNA damage response, cellular senescence
- MeSH terms
- Acetanilides, Bromodomain Containing Proteins, Animals, Azepines, Cell Line, Dose-Response Relationship, Drug, Fibroblasts, HeLa Cells, Heterocyclic Compounds, 3-Ring, Heterocyclic Compounds, 4 or More Rings, Humans, Morpholines, Nuclear Proteins, Pyrones, Transcription Factors, Triazoles, Blotting, Southern, Gene Expression, Telomere, In Situ Hybridization, Fluorescence, Cell Cycle Proteins, Telomerase, RNA Interference, Mice, Telomere Homeostasis, Telomere Shortening
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.